Loading company…
Rosetta Exosome develops exosome-based diagnostic and therapeutic technologies.
Founded in 2016 and based in Gyeonggi-do, South Korea, Rosetta Exosome develops platform technologies for exosome-based diagnostics and therapeutics. Its ExoLutE kit isolates extracellular vesicles from cell-conditioned media and biological fluids, supporting exosome production from microorganisms. In April 2021, the company raised KRW 8 billion in Series A funding led by DA Value Investment, with K Bridge Investment, Innopolis Partners, and DS & Partners participating.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in